– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study –– 70% of patients with SPMS and PPMS demonstrated stable or improved cognition after one year of Ocrevus treatment in.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at .
Clene Inc.February 19, 2021 GMT
SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim data from its REPAIR-MS study and updated blinded interim data from its VISIONARY-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis’ ACTRIMS Forum 2021 (“ACTRIMS”) taking place virtually from February 25-27, 2021.